Chiropractors in Adelphi, MD Accepting Medicare
7 Chiropractors found. Showing 1 - 7
 Dr. Mark Alan Shulman, M.A., D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd, Ste 108, Adelphi, MD 20783 Phone: 301-434-6932 Fax: 301-434-0920 |
 Dr. Michelle Lynn Williams, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd, Suite 208, Adelphi, MD 20783 Phone: 301-439-0381 Fax: 301-439-0383 |
Dr. Lori M. Cottman, D.C. Chiropractor - Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd, Suite 328, Adelphi, MD 20783 Phone: 301-328-0762 Fax: 301-328-0767 |
 Yousefi Chiropractic Clinic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd, Suite 108, Adelphi, MD 20783 Phone: 301-434-6932 |
Mi Ventures Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd Ste 208, Adelphi, MD 20783 Phone: 301-439-0381 Fax: 301-439-0383 |
Hyattsville Rehab Center, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd Ste 219, Adelphi, MD 20783 Phone: 703-214-1000 |
Alegre Chiropractic, Llc Chiropractor - Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7411 Riggs Rd, Suite 328, Adelphi, MD 20783 Phone: 301-328-0762 |
News Archive
Vitamin D levels of newborns appear to predict their risk of respiratory infections
The vitamin D levels of newborn babies appear to predict their risk of respiratory infections during infancy and the occurrence of wheezing during early childhood, but not the risk of developing asthma. Results of a study in the January 2011 issue of Pediatrics support the theory that widespread vitamin D deficiency contributes to risk of infections.
Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug
Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.
Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
GSK, Genmab to refocus on ofatumumab development program in autoimmune indications
GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.
› Verified 5 days ago